HUTCHMED (NASDAQ:HCM) Shares Gap Down - Time to Sell?

HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report)'s share price gapped down prior to trading on Tuesday . The stock had previously closed at $14.89, but opened at $14.50. HUTCHMED shares last traded at $14.35, with a volume of 8,301 shares.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised shares of HUTCHMED from a "hold" rating to a "buy" rating in a research note on Friday, March 21st.

HUTCHMED Trading Up 0.1 %

The company has a quick ratio of 2.68, a current ratio of 2.81 and a debt-to-equity ratio of 0.07. The company has a 50 day moving average of $14.81 and a 200-day moving average of $15.97.

Institutional Investors Weigh In On HUTCHMED

A number of large investors have recently made changes to their positions in the business. Public Employees Retirement System of Ohio lifted its stake in HUTCHMED by 49.6% in the fourth quarter. Public Employees Retirement System of Ohio now owns 2,710 shares of the company's stock worth $39,000 after acquiring an additional 899 shares during the period. Summit Trail Advisors LLC boosted its stake in shares of HUTCHMED by 14.4% during the 4th quarter. Summit Trail Advisors LLC now owns 13,090 shares of the company's stock valued at $189,000 after purchasing an additional 1,647 shares in the last quarter. Crossmark Global Holdings Inc. increased its position in shares of HUTCHMED by 10.7% during the fourth quarter. Crossmark Global Holdings Inc. now owns 18,591 shares of the company's stock valued at $268,000 after buying an additional 1,799 shares during the period. Barclays PLC lifted its holdings in HUTCHMED by 1,483.6% in the fourth quarter. Barclays PLC now owns 2,407 shares of the company's stock worth $35,000 after buying an additional 2,255 shares during the period. Finally, State Street Corp boosted its position in HUTCHMED by 0.9% during the 3rd quarter. State Street Corp now owns 349,524 shares of the company's stock valued at $6,826,000 after acquiring an additional 3,078 shares in the last quarter. 8.82% of the stock is currently owned by institutional investors.

About HUTCHMED

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.